+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efforts by commercial health plans to increase Chlamydia trachomatis screening among their members



Efforts by commercial health plans to increase Chlamydia trachomatis screening among their members



Sexually Transmitted Diseases 40(1): 55-60



The screening rate for Chlamydia trachomatis (Ct) is below 38% nationally, despite the high prevalence of Ct nationally and the low cost of both the screening test and the treatment. The purposes of this study are (a) to ascertain what activities commercial health plans have attempted (if any) to increase their Ct screening rates and (b) to identify barriers to improving Ct screening rates in commercial health plans. Qualitative research methods were used, including structured interviews. In-depth telephone interviews with commercial health plans were conducted to identify health plan activities that led to high Ct screening rates by providers. Plans were selected, which were either in the top or in the bottom quarter of all plans or had either an increase or decrease in Ct screening rates of at least 3 percentage points over the previous 2 to 3 years. Interviews were restricted to plans reporting Ct screening rates to the National Committee for Quality Assurance for at least 3 years, plans with enrollment of at least 500 commercially insured women aged 15 to 26 years, and plans that were not staff model-managed care plans. A total of 35 structured interviews were completed with a response rate of 64%. Overall Ct screening rates in commercial health plans are quite low, with a median rate of 35%. All interviewed plans-both successful and not successful-reimbursed for Ct screening and used clinical guidelines. All but 3 plans had some type of intervention in place designed to improve Ct screening rats. The interventions varied-some aimed at providers, others at patients, and others at data collection-but the health plans were actively trying to improve screening rates. Health plans identified several barriers to improving screening rates in the commercially insured population. These include difficulties in identifying sexually active members for screening, limited health plan resources to target the problem, concerns about contacting minors, and cultural barriers to discussing sexually transmitted diseases. Both high- and low-performing plans are actively trying to increase the Ct screening rates. However, efforts to date have not been successful, suggesting the need for alternative approaches to address existing barriers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052912062

Download citation: RISBibTeXText

PMID: 23254117

DOI: 10.1097/OLQ.0b013e31827657db


Related references

A decision analysis model to maximize the effectiveness of screening and treatment for Chlamydia trachomatis in US health plans A tool to respond to a new performance measure. International Journal of STD & AIDS 12(Supplement 2): 168, 2001

Screening for Chlamydia trachomatis infection using the BDProbeTecTM ET Chlamydia trachomatis amplified DNA assay on urine in a GUM clinic setting: A simple, fast and cost-effective alternative. International Journal of STD & AIDS 12(7): 430-436, July, 2001

Evaluation of a new commercial microimmunofluorescence test for detection of antibodies to Chlamydia pneumoniae, Chlamydia trachomatis, and Chlamydia psittaci. European Journal of Clinical Microbiology & Infectious Diseases 16(9): 685-688, 1997

Health plans increase efforts at giving teens a shot in the arm. Ahip Coverage 45(5): 62-4, 67, 2004

Evaluation of clinician-reported adherence to Centers for Disease Control and Prevention guidelines for the treatment of Chlamydia trachomatis in two U.S. health plans. Sexually Transmitted Diseases 33(4): 235-243, 2006

Screening for Chlamydia trachomatis at a university health service. Journal of Obstetric, Gynecologic, and Neonatal Nursing 18(2): 145-149, 1989

Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project. Bmj 335(7614): 291-291, 2007

Sexuality and health: the hidden costs of screening for Chlamydia trachomatis. Bmj 318(7188): 931-933, 1999

Screening asymptomatic males for Chlamydia trachomatis in school-based health centers. Pediatric Research 47(4 Part 2): 6A, April, 2000

Clinical and laboratory screening of Chlamydia trachomatis in women at a university health service. Journal of American College Health 36(1): 39-43, 1987

Measurement of IgG antibodies to Chlamydia trachomatis by commercial enzyme immunoassays and immunofluorescence in sera from pregnant women and patients with infertility, pelvic inflammatory disease, ectopic pregnancy, and laboratory diagnosed Chlamydia psittaci/Chlamydia pneumoniae infection. Journal of Clinical Pathology 56(3): 225-229, 2003

Public Health screening for Chlamydia trachomatis and Neisseria gonorrhoeae in adult detention facilities. Abstracts of the General Meeting of the American Society for Microbiology 101: 194, 2001

Chlamydia trachomatis, monoclonal antibody testing, wet mount screening, and the university health service. Journal of American College Health 37(2): 61-64, 1988

Screening for Chlamydia trachomatis urogenital infection among young men Visitors of the sexual health centre. International Journal of STD & AIDS 12(Supplement 2): 121, 2001